EA201692242A1 - Композиции с высокой концентрацией антител - Google Patents

Композиции с высокой концентрацией антител

Info

Publication number
EA201692242A1
EA201692242A1 EA201692242A EA201692242A EA201692242A1 EA 201692242 A1 EA201692242 A1 EA 201692242A1 EA 201692242 A EA201692242 A EA 201692242A EA 201692242 A EA201692242 A EA 201692242A EA 201692242 A1 EA201692242 A1 EA 201692242A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
antibody concentration
high antibody
sclerostin
immunoglobulin
Prior art date
Application number
EA201692242A
Other languages
English (en)
Other versions
EA037392B1 (ru
Inventor
Тимоти Д. Осслунд
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146975&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201692242A1 publication Critical patent/EA201692242A1/ru
Publication of EA037392B1 publication Critical patent/EA037392B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Данное изобретение описывает композиции с высокой концентрацией антител, включающие иммуноглобулин к склеростину и ацетатную соль и/или ацетатный буфер, и способы их использования.
EA201692242A 2010-05-14 2011-05-11 Композиции с высокой концентрацией антител EA037392B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33498610P 2010-05-14 2010-05-14

Publications (2)

Publication Number Publication Date
EA201692242A1 true EA201692242A1 (ru) 2017-11-30
EA037392B1 EA037392B1 (ru) 2021-03-23

Family

ID=44146975

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201692242A EA037392B1 (ru) 2010-05-14 2011-05-11 Композиции с высокой концентрацией антител
EA201291226A EA027039B1 (ru) 2010-05-14 2011-05-11 Композиции с высокой концентрацией антител
EA202092884A EA202092884A1 (ru) 2010-05-14 2011-05-11 Композиции с высокой концентрацией антител

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201291226A EA027039B1 (ru) 2010-05-14 2011-05-11 Композиции с высокой концентрацией антител
EA202092884A EA202092884A1 (ru) 2010-05-14 2011-05-11 Композиции с высокой концентрацией антител

Country Status (29)

Country Link
US (4) US9352043B2 (ru)
EP (3) EP3195880B1 (ru)
JP (6) JP5889877B2 (ru)
KR (3) KR102026038B1 (ru)
CN (1) CN102946903B (ru)
AU (1) AU2011250920B2 (ru)
BR (1) BR112012028920B1 (ru)
CA (1) CA2798888C (ru)
CL (1) CL2012003172A1 (ru)
CO (1) CO6640258A2 (ru)
CY (2) CY1119069T1 (ru)
DK (2) DK3195880T3 (ru)
EA (3) EA037392B1 (ru)
ES (2) ES2626033T3 (ru)
HN (1) HN2012002446A (ru)
HR (2) HRP20170983T1 (ru)
HU (2) HUE033315T2 (ru)
IL (3) IL295275A (ru)
LT (2) LT2569010T (ru)
ME (1) ME02819B (ru)
MX (1) MX2012013268A (ru)
PL (2) PL2569010T3 (ru)
PT (2) PT3195880T (ru)
RS (2) RS59993B1 (ru)
SG (3) SG10201912670XA (ru)
SI (2) SI2569010T1 (ru)
TW (4) TWI617570B (ru)
WO (1) WO2011143307A1 (ru)
ZA (1) ZA201208543B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
MX2009009912A (es) 2007-03-27 2010-01-18 Sea Lane Biotechnologies Llc Constructos y colecciones que comprenden secuencias de cadena ligera sustitutas de anticuerpos.
AU2010249046A1 (en) 2009-05-13 2011-12-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
ME02819B (me) 2010-05-14 2018-01-20 Amgen Inc Formulacije sa visokom koncentracijom antitijela
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
KR20190120401A (ko) * 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
BR112014031841A2 (pt) * 2012-06-21 2017-06-27 Ucb Pharma Sa formulação farmacêutica
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
EP3043774B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US9527922B2 (en) 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
ES2823798T3 (es) * 2014-12-31 2021-05-10 Dev Ct Biotechnology Anticuerpos humanizados específicos de alfa-enolasa y procedimientos de usos en la terapia del cáncer
TW201726111A (zh) * 2015-09-30 2017-08-01 持田製藥股份有限公司 含高濃度抗體之液體製劑
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN110461356A (zh) 2016-12-29 2019-11-15 迈阿密大学 用于调节肺中炎性体活性和炎症的方法
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US11590237B2 (en) * 2017-05-18 2023-02-28 Merck Sharp & Dohme Llc Pharmaceutical formulation comprising incretin-insulin conjugates
CN109952093B (zh) * 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
JP6544669B1 (ja) 2018-03-16 2019-07-17 ディヴェロップメント センター フォー バイオテクノロジー アルファエノラーゼに特異的な抗体及びその使用
SG11202008206TA (en) * 2018-03-30 2020-09-29 Amgen Inc C-terminal antibody variants
BR112020026798A2 (pt) * 2018-07-03 2021-03-30 University Of Miami Composições e métodos para o tratamento de doenças ou condições relacionadas com o inflamassoma
AR117628A1 (es) * 2018-07-31 2021-08-18 Amgen Inc Formulaciones y composiciones farmacéuticas que comprenden una proteína de unión a antígeno enmascarada
KR20210043607A (ko) * 2018-08-10 2021-04-21 암젠 인크 항체 제약 제형의 제조 방법
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
CN114703067B (zh) * 2022-04-06 2023-09-05 上海光玥生物科技有限公司 一种光合微生物及其用途和质粒

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
JPS5889877A (ja) 1981-11-21 1983-05-28 Nippon Telegr & Teleph Corp <Ntt> 超伝導回路装置
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
AU662304B2 (en) 1990-10-22 1995-08-31 Fox Chase Cancer Center DNA construct for providing RNA therapy
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
WO1994028929A1 (en) 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2187902A1 (en) 1994-04-29 1995-11-09 Peter Ten Dijke Morphogenic protein-specific cell surface receptors and uses therefor
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996039486A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
JP4124486B2 (ja) 1996-05-22 2008-07-23 ビベンティア バイオテック インコーポレイテッド ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
AU8555798A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2361553A1 (en) 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof
AU4851900A (en) 1999-06-09 2000-12-28 Genentech Inc. Compositions and methods for the treatment of tumor
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP4141095B2 (ja) 1999-10-29 2008-08-27 三洋電機株式会社 半導体装置とその製造方法
EP1266000A1 (en) 2000-03-02 2002-12-18 Amgen Inc. Chordin-like-2 molecules and uses thereof
CA2410912A1 (en) 2000-06-01 2001-12-06 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
JP2004520005A (ja) 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー オステオレビン遺伝子多型性
AU2002216610A1 (en) 2000-09-01 2002-04-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
WO2003050513A2 (en) 2001-12-06 2003-06-19 Biocontrol Systems, Inc. Sample collection and testing system
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP4662714B2 (ja) 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US7758876B2 (en) 2002-11-01 2010-07-20 The United States Of America As Represented By The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
JP4660471B2 (ja) 2003-03-14 2011-03-30 セルテック アール アンド ディー， インコーポレイテッド ＴＧＦβ結合タンパク質のリガンドおよびその使用
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7390786B2 (en) 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
EA200901031A1 (ru) 2007-02-02 2010-04-30 Новартис Аг Модуляторы склеростин-связывающих партнеров для лечения костных расстройств
MY149129A (en) 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2209491B1 (en) 2007-11-02 2015-10-28 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
CN101896201A (zh) 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
CN102083459A (zh) * 2008-05-23 2011-06-01 诺沃-诺迪斯克保健股份有限公司 包括含有peg化的gla-结构域的蛋白质的低粘度组合物
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
ME02819B (me) * 2010-05-14 2018-01-20 Amgen Inc Formulacije sa visokom koncentracijom antitijela
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP3838922A1 (en) 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
MY166429A (en) * 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody

Also Published As

Publication number Publication date
KR20190109600A (ko) 2019-09-25
TWI617570B (zh) 2018-03-11
EP3620175A1 (en) 2020-03-11
MX2012013268A (es) 2013-05-28
EP3195880B1 (en) 2019-11-27
US9352043B2 (en) 2016-05-31
EA037392B1 (ru) 2021-03-23
DK3195880T3 (da) 2020-03-02
RS59993B1 (sr) 2020-04-30
DK2569010T3 (en) 2017-06-26
HUE033315T2 (en) 2017-11-28
IL264636A (ru) 2019-03-31
ZA201208543B (en) 2021-10-27
JP2016138110A (ja) 2016-08-04
ME02819B (me) 2018-01-20
IL264636B (en) 2022-09-01
PT2569010T (pt) 2017-05-31
IL223014B (en) 2019-02-28
JP6416336B2 (ja) 2018-10-31
TW201706304A (zh) 2017-02-16
HN2012002446A (es) 2015-08-03
CO6640258A2 (es) 2013-03-22
US20190022230A1 (en) 2019-01-24
HRP20200268T1 (hr) 2020-05-29
JP7267707B2 (ja) 2023-05-02
AU2011250920A1 (en) 2012-12-20
BR112012028920B1 (pt) 2021-03-23
EP3195880A1 (en) 2017-07-26
EA202092884A1 (ru) 2022-01-31
ES2626033T3 (es) 2017-07-21
CY1122669T1 (el) 2021-03-12
JP2023182702A (ja) 2023-12-26
CA2798888A1 (en) 2011-11-17
SI3195880T1 (sl) 2020-03-31
TWI759634B (zh) 2022-04-01
SG185465A1 (en) 2012-12-28
KR102220879B1 (ko) 2021-02-26
KR101861867B1 (ko) 2018-05-29
KR102026038B1 (ko) 2019-09-26
KR20130117650A (ko) 2013-10-28
RS56210B1 (sr) 2017-11-30
WO2011143307A1 (en) 2011-11-17
US20160235849A1 (en) 2016-08-18
CY1119069T1 (el) 2018-01-10
CN102946903B (zh) 2014-11-26
US10064946B2 (en) 2018-09-04
TWI689517B (zh) 2020-04-01
SG10201701869YA (en) 2017-04-27
HRP20170983T1 (hr) 2017-09-22
US11040102B2 (en) 2021-06-22
PL3195880T3 (pl) 2020-06-01
SG10201912670XA (en) 2020-02-27
US20130202620A1 (en) 2013-08-08
AU2011250920B2 (en) 2015-05-21
HUE047492T2 (hu) 2020-04-28
JP2017222674A (ja) 2017-12-21
KR20180056803A (ko) 2018-05-29
ES2773031T3 (es) 2020-07-09
TW202017941A (zh) 2020-05-16
EA201291226A1 (ru) 2013-04-30
US20210275671A1 (en) 2021-09-09
JP5889877B2 (ja) 2016-03-30
CL2012003172A1 (es) 2013-11-29
BR112012028920A2 (pt) 2017-03-14
JP2013527176A (ja) 2013-06-27
SI2569010T1 (sl) 2017-09-29
JP6174176B2 (ja) 2017-08-02
JP2019031515A (ja) 2019-02-28
CN102946903A (zh) 2013-02-27
CA2798888C (en) 2019-10-01
JP2022000436A (ja) 2022-01-04
LT2569010T (lt) 2017-08-10
IL295275A (en) 2022-10-01
LT3195880T (lt) 2020-01-10
EP2569010A1 (en) 2013-03-20
EP2569010B1 (en) 2017-04-12
EA027039B1 (ru) 2017-06-30
PL2569010T3 (pl) 2017-09-29
PT3195880T (pt) 2020-02-21
TW201144326A (en) 2011-12-16
IL223014A0 (en) 2013-02-03
TW202241510A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
EA201692242A1 (ru) Композиции с высокой концентрацией антител
CY1123145T1 (el) Anti-cd40 αντισωματα
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
UA116873C2 (uk) Антитіло, яке зв&#39;язується з ox40
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX347020B (es) Anticuerpo contra el csf-1r.
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201390467A1 (ru) Композиции антител и способы применения
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
EA201300239A1 (ru) Антитела к fap и способы их применения
GT201400045A (es) Anticuerpo anti-abtcr
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM